GRI Bio (GRI) Other Non-Current Liabilities (2020 - 2024)
GRI Bio (GRI) posted quarterly Other Non-Current Liabilities of $1000.0 for Q1 2024, down 99.46% year-over-year from $185000.0 in Q2 2023, and down 66.67% quarter-over-quarter from $3000.0 in Q4 2023.
GRI Bio (GRI) Other Non-Current Liabilities (2020 - 2024) Analysis & Trends
GRI Bio's Other Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $1000.0 for Q1 2024.
- In Q1 2024, Other Non-Current Liabilities fell 99.46% year-over-year to $1000.0; the TTM figure through Mar 2024 stood at $1000.0 (down 99.46% YoY), while the FY2023 annual figure was $3000.0, changed N/A from the prior year.
- Other Non-Current Liabilities for Q1 2024 stood at $1000.0, down from $3000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $225000.0 in Q3 2022, with the low at $1000.0 in Q1 2024.
- The 5-year median for Other Non-Current Liabilities is $67500.0 (2021), against an average of $85250.0.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities jumped 302.17% in 2023, then tumbled 99.46% in 2024.
- GRI Bio's Other Non-Current Liabilities stood at $170000.0 in 2020, then plunged by 57.65% to $72000.0 in 2021, then soared by 212.5% to $225000.0 in 2022, then slumped by 98.67% to $3000.0 in 2023, then slumped by 66.67% to $1000.0 in 2024.
- Business Quant data shows GRI's Other Non-Current Liabilities at $1000.0 in Q1 2024, $3000.0 in Q4 2023, and $18000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | GRI Bio | 3.01 Mn | 3.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 18,000.00 |
| Jun 30, 2023 | 63,000.00 |
| Mar 31, 2023 | 185,000.00 |
| Sep 30, 2022 | 225,000.00 |
| Jun 30, 2022 | 19,000.00 |
| Mar 31, 2022 | 46,000.00 |
| Dec 31, 2021 | 72,000.00 |
| Sep 30, 2021 | 98,000.00 |
| Jun 30, 2021 | 123,000.00 |
| Dec 31, 2020 | 170,000.00 |